Bristol Myers Squibb expanded its enterprise AI strategy by partnering with Anthropic to deploy Claude across global operations, aiming to move beyond chat-only use cases. The collaboration will integrate Claude AI across research, clinical development, manufacturing, commercial operations, and corporate functions for more than 30,000 employees. BMS said the platform is designed as a shared intelligence layer and will focus on embedding AI agents into drug-development workflows, including trial documentation support and regulatory-submission drafting. BMS also described near-term priorities spanning engineering acceleration with Claude Code and workflow integration for trial operations and safety narratives. The company positioned the effort as a shift toward agentic capabilities that can operate within day-to-day processes rather than producing standalone answers. For the sector, the announcement underscores that large pharma is prioritizing operationally grounded AI systems tied to structured data, documentation outputs, and compliance-relevant workflows.